Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

20201,771 citationsJournal Articlebronze Open Access

Authors

Deepak L. Bhatt · Brigham and Women's Hospital

Michael Szarek · State University of New York

Philippe Gabríel Steg · Inserm

Christopher P. Cannon · Brigham and Women's Hospital

Lawrence A. Leiter · St. Michael's Hospital

Darren K. McGuire · Parkland Health & Hospital System

Julia B. Lewis

Abstract

In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.).

Topics & Keywords

Diabetes Treatment and Management Cardiovascular Function and Risk Factors Parkinson's Disease Mechanisms and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 384, Issue 2, pp. 117-128

DOI: 10.1056/nejmoa2030183

Field-Weighted Citation Impact: 165.96